Eberconazole. WAS 2160.
D000935:Antifungal Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D003508:Cycloheptanes / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D015507:Drugs, Investigational / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D005658:Fungi / Q000187:drug effects; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D009181:Mycoses / Q000188:drug therapy* / Q000382:microbiology
D000935:Antifungal Agents; D003508:Cycloheptanes; D015507:Drugs, Investigational; D007093:Imidazoles; C118963:eberconazole